The present data show evidence that masitinib downregulates MCs infiltration and differentiation and prevents microvascular pathology by inhibiting SCF/c-Kit signaling, which could be fueled by the strong upregulation of SCF in reactive astrocytes in ALS mice [36]. Here, KIT is linked to amyotrophic lateral sclerosis.